In a report released today, Ami Fadia from Needham maintained a Buy rating on MapLight Therapeutics, Inc., with a price target of $37.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia has given his Buy rating due to a combination of factors discussed during a recent investor dinner with MapLight’s leadership team, which strengthened her conviction in the company’s lead program, ML-007, across schizophrenia and Alzheimer’s-related psychosis. She also sees favorable risk‑reward supported by clear success benchmarks for upcoming ZEPHYR data and believes management’s strategy for ML-007C-MA is well aligned with clinical and commercial expectations.
In addition, Fadia views early real‑world feedback on Cobenfy, the evolving muscarinic competitive landscape, and the progress of ML-004’s Phase 2 IRIS trial in Autism Spectrum Disorder as attractive growth drivers, with further upside from the broader pipeline. With these elements reinforcing her confidence and no change to her valuation framework, she maintains a Buy rating and keeps her price target at $37, reflecting meaningful upside from current levels.
In another report released on May 15, Morgan Stanley also maintained a Buy rating on the stock with a $29.29 price target.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MPLT in relation to earlier this year.